BriaCell Therapeutics Corp. (BCT.TO)
Toronto · CAD · Healthcare · Biotechnology
CA$4.87 (+1.67%) as of
Key statistics
- Market cap
- 42.37M
- Forward P/E
- -9.02
- EPS (TTM)
- -1.2700
- Dividend yield
- 0.00%
- 52-week range
- 3.6800 – 19.2400
- Beta
- 1.51
- Profit margin
- 0.00%
- Volume
- 4.08k
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- West Vancouver, BC, Canada
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.